Apotex Corp., headquartered in Weston, Florida, is the U.S. subsidiary of Apotex Inc., the 7th largest generic pharmaceutical company in the world. Apotex produces more than 500 products - with over 300 more in development - and markets in over 120 countries globally. As a result of substantial growth, Apotex Corp. is now ranked in the top 10 U.S. generic pharmaceutical companies.
In March of 2015, Apotex CEO andvPresident, Dr. Jeremy B. Desai, announced a company-wide realignment and new executive leadership team to better serve the healthcare market globally. “The result of these structural changes will be a performance-driven Apotex with improved customer focus, which is better able to capitalize on emerging opportunities in our rapidly evolving industry,” said Dr. Desai.
Under the new structure, Apotex will focus on three core areas: Global Generics, Global Specialty Pharma - which includes the development and manufacturing of biosimilars - and Global APIs. “The three principal objectives with this new model are to focus all of Apotex on a core strategy - align with our global customers, improve our capabilities in all disciplines and areas, and work together with greater collaboration and agility around common goals,” said Dr. Desai.
Apotex employs over 10,000 people globally, and can produce up to 24 billion dosages a year across a full range of dosage forms, including tablets, capsules, oral suspensions, ophthalmic, nasals, and a full range of liquid products. The company’s expansive product portfolio spans a wide range of therapeutic classes, including cardiovascular, anti-infective, gastrointestinal, central nervous system, mental health, and pain management.
Apotex has historically been aggressive in its approach to research and development - and that hasn’t changed. The company will spend $2 billion in the next ten years on R&D, with a significant portion of that focused on the company’s emerging biosimilar program. “We are very pleased to be at the forefront of companies who will introduce high quality biosimilar products into the U.S. marketplace,” said Dr. Desai. “Our entry into this new frontier of medicine is a watershed event in Apotex’s 40-year history of providing quality, affordable medicines to patients in need around the globe.”
In late 2014, Apotex announced that the FDA accepted the company’s filing for pegfilgrastim, a biosimilar version of Amgen’s Neulasta® - the long-acting formulation of Neupogen® (filgrastim), used to help cancer patients undergoing chemotherapy fight infections and fever by boosting white blood cell count. “The benefits for patients, payers and providers from biosimilars will be significant,” said Dr. Desai. “We are dedicated to playing a leading role in the effort to increase the American public’s access to more affordable versions of these life-saving therapies and generate substantial savings for the U.S. healthcare system.”
Apotex believes all manufacturers have a corporate citizenship responsibility to the global community. The company executes this responsibility through various national initiatives and partnerships, and continues to donate life-saving medicines to developing countries to alleviate human suffering and save the lives of people around the world. Apotex is committed to serving patients by advancing generics and providing high-quality, affordable products.
For more information, visit www.apotexcorp.com.